Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07367516 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Sep 2026 → Feb 2027
See other at-risk trials from Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Record History

  1. Primary completion pushed from Sep 2026 to Feb 2027 Eligibility criteria expanded, about 104 words · Secondary endpoints: details revised at 3 of 9 entries · Site details revised at 6 of 30 sites Show 3 more changesShow less
    • Eligibility criteria expanded, about 104 words
    • Secondary endpoints: details revised at 3 of 9 entries
    • Site details revised at 6 of 30 sites
  2. Eligibility criteria revised Study title expanded, about 1 wordv3 Show 1 more changeShow less
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 2026 to Feb 12, 2026 · Site details revised at 30 of 30 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Mar 2026 to Feb 12, 2026
    • Site details revised at 30 of 30 sites
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy. The Phase II stage primarily aims to evaluate the efficacy of TQB6411 Injection in this same participants population.
Trial Details
NCT Number NCT07367516
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Esophageal Cancer
Enrollment 105 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov